Picture of Multiqure SA logo

MQR — Multiqure SA Share Price

0.000.00%
pl flag iconLast trade - 00:00
IndustrialsHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+8.92%
3m-28.54%
6m-49.3%
1yr-71.14%
Volume Change (%)
10d/3m-4.11%
Price vs... (%)
52w High-75.9%
50d MA-32.75%
200d MA-42%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202631st Dec 2027
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2026 / 2027

Blurred out image of Multiqure SA EPS forecast chart

Profile Summary

Multiqure SA, formerly known as Pure Biologics SA is a Poland-based biotechnology company engaged in the discovery and development of biologic drug candidates. The Company focuses on research and development activities in oncology and other therapeutic areas. Its technology platforms include antibody- and aptamer-based solutions used in the identification and development of therapeutic candidates targeting specific biological pathways. The Company's pipeline comprises biologic drug candidates, including PB003G, PB004 and PBA-0405. The Company conducts research in immuno-oncology and develops therapeutic programs aimed at addressing unmet medical needs through innovative biologic approaches. In addition to drug discovery activities, it undertakes preclinical research and development work related to the advancement of its therapeutic candidates.

Directors

Last Annual
December 31st, 2025
Last Interim
June 30th, 2026
Incorporated
January 10th, 2018
Public Since
December 11th, 2018
No. of Employees
8
Sector
Professional & Commercial Services
Industry
Industrials
Exchange
pl flag iconWarsaw Stock Exchange
Shares in Issue
225,749,319
Blurred out image of a map
Address
Szczytnicka 11, WROCLAW, 50-382
Web
https://purebiologics.com/
Phone
Auditors
B-think Audit sp. Z o.o.

MQR Share Price Performance

FAQ